Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $196 from $194 and keeps an Overweight rating on the shares, noting that Auvelity Q3 sales were about 6% above consensus expectations. After updating the firm’s model for the quarter, the firm slightly increased FY25 estimates for Auvelity and Sunosi given Q3 beats, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $178 from $176 at BofA
- Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
- Axsome Therapeutics Reports Strong Q3 2025 Growth
- Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion
- Axsome Therapeutics files automatic mixed securities shelf